Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention-Reference-Cited by-同舟云学术

Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

Published:2020-10-02 Issue:3 Volume:109 Page:705-715
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Lee Craig R.¹,Thomas Cameron D.²,Beitelshees Amber L.³,Tuteja Sony⁴,Empey Philip E.⁵,Lee James C.⁶,Limdi Nita A.⁷,Duarte Julio D.²,Skaar Todd C.⁸,Chen Yiqing²,Cook Kelsey J.²,Coons James C.⁵,Dillon Chrisly⁷,Franchi Francesco⁹,Giri Jay⁴,Gong Yan²,Kreutz Rolf P.⁸,McDonough Caitrin W.²,Stevenson James M.⁵,Weck Karen E.¹⁰,Angiolillo Dominick J.⁹,Johnson Julie A.²,Stouffer George A.¹⁰,Cavallari Larisa H.²,

Affiliation:

1. Division of Pharmacotherapy and Experimental Therapeutics UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

2. Department of Pharmacotherapy and Translational Research Center for Pharmacogenomics and Precision Medicine University of Florida Gainesville Florida USA

3. University of Maryland School of Medicine Baltimore Maryland USA

4. University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA

5. School of Pharmacy University of Pittsburgh Pittsburgh Pennsylvania USA

6. Department of Pharmacy Practice University of Illinois at Chicago Chicago Illinois USA

7. University of Alabama at Birmingham Birmingham Alabama USA

8. Indiana University School of Medicine Indianapolis Indiana USA

9. Department of Medicine Division of Cardiology University of Florida Jacksonville Florida USA

10. Division of Cardiology and McAllister Heart Institute UNC School of Medicine University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2039

Reference46 articles.

1. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association

2. ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy

3. Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016

4. Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

5. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications;Interventional Cardiology Clinics;2024-10

2. Genotype-Guided Antiplatelet Therapy;Journal of the American College of Cardiology;2024-09

3. Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned;Clinical Pharmacology & Therapeutics;2024-08-21

4. CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association;Circulation;2024-08-06

5. CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention;Journal of the American Heart Association;2024-06-18